Physician profile
Khurram A Butt
NPI 1437149176
$668.21
in general payments reported to CMS, 2019-2025
14 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $249 · 2021: $191 · 2024: $45.42 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $167.64 | 2020-2025 | |
| Lilly USA, LLC | $93.74 | 2020-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $84.53 | 2020-2021 | |
| Medtronic, INC. | $74.21 | 2025 | |
| Abbott Laboratories | $45.90 | 2025 | Aveir |
| Astrazeneca Pharmaceuticals Lp | $33.74 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $27.88 | 2021 | |
| Merck Sharp & Dohme LLC | $26.33 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.48 | 2020 | |
| Xeris Pharmaceuticals, INC. | $24.81 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $21.00 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $16.57 | 2024 | |
| Biogen, INC. | $15.03 | 2024 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.